Moderna just moved one step closer to bringing mRNA-1345, an RSV shot, to market

The U.S. Food and Drug Administration granted the experimental shot fast-track designation in August 2021

Now, Moderna’s mRNA RSV shot has been given Breakthrough Therapy Designation, which allows for faster development and an expedited review period

RSV is usually not serious; most people experience only mild, cold-like symptoms and recover on their own in a week or two

Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023

Along with Moderna’s mRNA RSV shot, Pfizer and GSK have also developed RSV vaccines that are awaiting regulatory approval

Poster Comment:

They also are approving mRNA vaxxes for animals.